Novo Nordisk (Ozempic)

7073.649 - 7099.707 Ben Gilbert

So of the 69% that even make it into clinical development, you've got 36% left at graduating phase one, then 13% left graduating phase two, Then all the way at the end, 8% graduating out of phase three. So it gets pretty winnowed down over that course. But to your point, it's a big deal to enter phase three because it shows that you are one of the 13% that have made it this far.